<!DOCTYPE html>
<html>

<head>
	<meta charset="UTF-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title>Prosthetic Joint Infections</title>
	<link href="/index.css" type="text/css" rel="stylesheet">
	<script src="//code.jquery.com/jquery-1.10.2.js"></script>
	<script>
		$(function () {
			$("header").load("/header.html");
			$("footer").load("/footer.html");
		});
	</script>
	<script>
		function navDrop() {
			var x = document.getElementById('navlinks');
			if (x.style.display === 'flex') {
				x.style.display = 'none';
			} else {
				x.style.display = 'flex';
			}
		}
	</script>
</head>

<body>
	<header></header>
	<div class="spacer"></div>
	<div class="main">
		<h1 id="orthopedic-device-infection">Orthopedic Device Infection</h1>
		<h2 id="prosthetic-joint-infections">Prosthetic Joint Infections</h2>
		<h3 id="prosthetic-joints">Prosthetic joints</h3>
		<h4 id="definitive">Definitive</h4>
		<ul>
			<li>
				<p>Presence of a sinus tract, which is directly communicating to the prosthesis.</p>
			</li>
			<li>
				<p>Evidence of purulence surrounding the prosthesis without contiguous site of infection.</p>
			</li>
			<li>
				<p>Two or more intra-operative positive cultures that yield the same organism.</p>
			</li>
			<li>
				<p>Growth of <em>Staphylococcus aureus</em> in a single culture tissue or synovial fluid.</p>
			</li>
		</ul>
		<h4 id="suggestive">Suggestive</h4>
		<ul>
			<li>
				<p>Evidence of acute inflammation of the peri-prosthetic tissue.</p>
			</li>
		</ul>
		<p>Treatment of PJI following debridement and retention of prosthesis (see <strong><a
					href="#pji-treatment">Table 2</a></strong>).</p>
		<h3 id="pji-due-to-staphylococcus-infection">PJI Due to Staphylococcus infection</h3>
		<p>2&ndash;6 weeks of pathogen-directed IV antibiotics in combination with Rifampin 600 mg PO QD followed by
			Rifampin, plus a companion oral drug (Ciprofloxacin or Levofloxacin).</p>
		</p>
		<ul>
			<li>
				<p>Guidelines indicate using 300&ndash;450 mg PO QD</p>
			</li>
		</ul>
		<p>Secondary companion drugs include:</p>
		<ul>
			<li>
				<p>Doxycycline</p>
			</li>
			<li>
				<p>Cephalexin</p>
			</li>
			<li>
				<p>Dicloxacillin</p>
			</li>
		</ul>
		<p>If Rifampin cannot be used due to allergy or intolerance, proceed with 4&ndash;6 weeks of pathogen-directed
			IV therapy.</p>
		<h4>Chronic Suppressive Therapy</h4>
		<ul>
			<li>
				<p>Cephalexin, Dicloxacillin, Minocycline based on in vitro susceptibilities.</p>
			</li>
			<li>
				<p>Rifampin alone, or combination therapy is generally not recommended for chronic suppressive therapy.
				</p>
			</li>
		</ul>
		<p>For suppressive therapy (Oral): see <strong><a href="#pji-treatment">Table 2</a></strong>.</p>
		<h3 id="pji-secondary-to-other-pathogens">PJI secondary to other pathogens</h3>
		<p>4–6 weeks of pathogen-directed IV or highly bioavailable oral</p>
		<h3 id="pji-management">Management</h3>
		<hr />
		<figure>
			<img src="/figures/pji-algorithm.png">
			<figcaption><strong>Figure 1.</strong> Algorithm for treatment of prosthetic joint infections.</figcaption>
		</figure>
		<hr />
		<h4
			id="medical-management-of-pji-following-resection-arthroplasty-with-or-without-planned-staged-reimplantation">
			Medical management of PJI following resection arthroplasty with or without planned staged reimplantation
		</h4>
		<p>4–6 weeks of pathogen-specific IV or highly bioavailable oral antimicrobial therapy</p>
		<p>Monitoring of outpatient intravenous antimicrobial therapy with inflammatory markers (CRP, ESR) and CMP and
			CBC.</p>
		<h4 id="medical-management-for-a-patient-with-pji-following-1-stage-exchange">Medical management for a patient
			with PJI
			following 1-stage exchange?</h4>
		<p>Less commonly preferred in the U.S. compared to Europe.</p>
		<h4 id="medical-management-for-a-patient-with-pji-following-2-stage-exchange">Medical management for a patient
			with PJI
			following 2-stage exchange?</h4>
		<p>Management of MSSA/MSSE and/or MRSA/MRSE: IV or PO regimen for 4–6 weeks post explantation of infected
			device.</p>
		<p>Antimicrobials should have activity against infecting organisms.</p>
		<h4 id="medical-treatment-for-a-patient-with-pji-following-amputation">Medical treatment for a patient with PJI
			following amputation:</h4>
		<p>If evidence of residual infected bone and soft tissue (THA Infection, TKA prosthesis above level of
			amputation), plan for 4-6 weeks of pathogen-specific IV or highly bioavailable oral antimicrobial therapy.
		</p>
		<p>If after amputation, all infected bone and soft tissue has been surgically removed and it has been
			ascertained that there is no concomitant sepsis or bacteremia, treat with pathogen-directed therapy for
			24-48 hours after amputation.</p>
		<hr />
		<div class="table">
			<table width=400px>
				<caption><strong>Table 1.</strong> Common Antimicrobials Used for Chronic Oral Antimicrobial Suppression
					(B-III
					Unless Otherwise Stated in Text)<sup>a,b</sup></p>
				</caption>
				<thead>
					<tr>
						<th>Microorganism</th>
						<th>Preferred Treatment</th>
						<th>Alternative Treatment</th>
					</tr>
				</thead>
				<tbody>
					<tr>
						<td>Staphylococci, oxacillin-susceptible </td>
						<td>Cephalexin 500 mg PO tid or qid <br>or<br>Cefadroxil 500 mg PO bid </td>
						<td>Dicloxacillin 500 mg PO tid or qid<br>Clindamycin 300 mg PO
							qid<br>Amoxicillin-clavulanate 500 mg PO tid </td>
					</tr>
					<tr>
						<td>Staphylococci, oxacillin-resistant </td>
						<td>Cotrimoxazole 1 DS tab PO bid <br>Minocycline or doxycycline100 mg PO bid
						</td>
						<td> </td>
					</tr>
					<tr>
						<td>β-hemolytic streptococci </td>
						<td>Penicillin V 500 mg PO bid to qid <br>or <br>Amoxicillin 500 mg PO tid
						</td>
						<td>Cephalexin 500 mg PO tid or qid </td>
					</tr>
					<tr>
						<td><em>Enterococcus</em> spp, penicillin susceptible </td>
						<td>Penicillin V 500 mg PO bid to qid <br>or <br>Amoxicillin 500 mg PO tid
						</td>
						<td> </td>
					</tr>
					<tr>
						<td><em>Pseudomonas aeruginosa</em> </td>
						<td>Ciprofloxacin 250–500 mg PO bid </td>
						<td> </td>
					</tr>
					<tr>
						<td>Enterobacteriaceae </td>
						<td>Cotrimoxazole 1 DS tab PO bid </td>
						<td>β-lactam oral therapy based on in vitro susceptibilities </td>
					</tr>
					<tr>
						<td><em>Propionibacterium</em> spp </td>
						<td>Penicillin V 500 mg PO bid to qid <br>or<br>Amoxicillin 500 mg PO tid
						</td>
						<td>Cephalexin 500 mg PO tid or qid <br><br>Minocycline or doxycycline 100 mg PO
							bid </td>
					</tr>
				</tbody>
			</table>
			<p>Abbreviations: bid, twice daily; DS, double strength; PO, per oral; qid, 4 times daily; tid, 3 times
				daily.</p>
			<p><sup>a</sup> Antimicrobial dosage needs to be adjusted based on patients' renal and hepatic function.
				Antimicrobials should be chosen based on in vitro susceptibility as well as patient drug allergies,
				intolerances, and potential drug interactions or contraindications to a specific antimicrobial.</p>
			<p><sup>b</sup> Clinical and laboratory monitoring for efficacy and safety should occur based on the
				clinical judgment of the clinician caring for the patient. The possibility of prolonged QTc interval and
				tendinopathy should be discussed and monitored when using fluoroquinolones. The possibility of
				<em>Clostridium difficile</em> colitis should also be discussed when using any antimicrobial.
			</p>
		</div>
	</div>
	<hr />
	<div class="table">
		<table width=1000px>
			<caption><strong>Table 2.</strong> Intravenous or Highly Bioavailable Oral Antimicrobial Treatment of Common
				Microorganisms Causing Prosthetic Joint Infection (B-III Unless Otherwise Stated in Text).</caption>
			<thead>
				<tr>
					<th>Microorganism </th>
					<th>Preferred Treatment<sup>a</sup></th>
					<th>Alternative Treatment<sup>a</sup></th>
					<th>Comments </th>
				</tr>
			</thead>
			<tbody>
				<tr>
					<td rowspan="5">Staphylococci, oxacillin-susceptible </td>
					<td>Nafcillin<sup>b</sup> sodium 1.5–2 g IV q4-6 h </td>
					<td>Vancomycin IV 15 mg/kg q12 h </td>
					<td rowspan="5">See recommended use of rifampin as a companion drug for rifampin-susceptible PJI
						treated with debridement and retention or 1-stage exchange in text </td>
				</tr>
				<tr>
					<td>or</td>
					<td>or</td>
				</tr>
				<tr>
					<td>Cefazolin 1–2 g IV q8 h </td>
					<td>Daptomycin 6 mg/kg IV q 24 h </td>
				</tr>
				<tr>
					<td>or</td>
					<td>or</td>
				</tr>
				<tr>
					<td>Ceftriaxone<sup>c</sup> 1–2 g IV q24 h </td>
					<td>Linezolid 600 mg PO/IV every 12 h </td>
				</tr>
				<tr>
					<td>Staphylococci, oxacillin-resistant </td>
					<td>Vancomycin<sup>d</sup> IV 15 mg/kg q12 h </td>
					<td>Daptomycin 6 mg/kg IV q24 horLinezolid 600 mg PO/IV q12 h </td>
					<td>See recommended use of rifampin as a companion drug for rifampin-susceptible PJI treated with
						debridement and retention or 1-stage exchange in text </td>
				</tr>
				<tr>
					<td><em>Enterococcus</em> spp, penicillin-susceptible </td>
					<td>Penicillin G 20–24 million units IV q24 h continuously or in 6 divided doses
						<br>or<br>Ampicillin sodium 12 g IV q24 h continuously or in 6 divided doses
					</td>
					<td>Vancomycin 15 mg/kg IV q12 h <br><br>or <br>Daptomycin 6 mg/kg IV q24 h </td>
					<td>4–6 wk. Aminoglycoside optional <br><br>Vancomycin should be used only in case of
						penicillin allergy </td>
				</tr>
				<tr>
					<td> </td>
					<td> </td>
					<td>or </td>
					<td> </td>
				</tr>
				<tr>
					<td> </td>
					<td> </td>
					<td>Linezolid 600 mg PO or <br> IV q12 h </td>
					<td> </td>
				</tr>
				<tr>
					<td><em>Enterococcus</em> spp, penicillin-resistant </td>
					<td>Vancomycin 15 mg/kg IV q12 h </td>
					<td>Linezolid 600 mg PO or <br><br>IV q12 h <br><br>or <br>Daptomycin 6 mg IV q24 h
					</td>
					<td>4–6 wk. Addition of aminoglycoside optional </td>
				</tr>
				<tr>
					<td><em>Pseudomonas aeruginosa</em> </td>
					<td>Cefepime 2 g IV q12 h </td>
					<td>Ciprofloxacin 750 mg PO bid </td>
					<td>4–6 wk </td>
				</tr>
				<tr>
					<td> </td>
					<td>or </td>
					<td>or 400 mg IV q12 h </td>
					<td>Addition of aminoglycoside optional </td>
				</tr>
				<tr>
					<td> </td>
					<td>Meropenem<sup>e</sup> 1 g IV q8 h </td>
					<td>or </td>
					<td rowspan="2">Use of 2 active drugs could be considered based on clinical circumstance of patient.
						If aminoglycoside in spacer, and organism aminoglycoside susceptible than double coverage being
						provided with recommended IV or oral monotherapy </td>
				</tr>
				<tr>
					<td> </td>
					<td> </td>
					<td>Ceftazidime 2 g IV q8 h </td>
				</tr>
				<tr>
					<td><em>Enterobacter</em> spp </td>
					<td>Cefepime 2 g IV q12 h <br>or <br>Ertapenem 1 g IV q24 h </td>
					<td>Ciprofloxacin 750 mg PO <br> or 400 mg IV q12 h </td>
					<td>4–6 wk. </td>
				</tr>
				<tr>
					<td>Enterobacteriaceae </td>
					<td>IV β-lactam based on in vitro susceptibilities or <br>Ciprofloxacin 750 mg PO bid
					</td>
					<td> </td>
					<td>4–6 wk </td>
				</tr>
				<tr>
					<td>β-hemolytic streptococci </td>
					<td>Penicillin G 20–24 million units IV q24 h continuously or in 6 divided doses <br>or
						<br>Ceftriaxone 2 g IV q24 h
					</td>
					<td>Vancomycin 15 mg/kg IV q12 h </td>
					<td>4–6 wk <br>Vancomycin only in case of allergy </td>
				</tr>
				<tr>
					<td><em>Propionibacterium acnes</em> </td>
					<td>Penicillin G 20 million units IV q24 h continuously or in 6 divided doses <br>or <br>Ceftriaxone
						2 g IV q24 h </td>
					<td>Clindamycin 600–900 mg IV q8 h or clindamycin 300–450 mg PO qid <br>or <br>Vancomycin
						15 mg/kg IV q12 h </td>
					<td>4–6 wk <br><br>Vancomycin only in case of allergy </td>
				</tr>
			</tbody>
		</table>
		<p>Abbreviations: bid, twice daily; IV, intravenous; PJI, prosthetic joint infection; q, every; PO, per oral;
			qid, 4 times daily.</p>
		<p><sup>a</sup> Antimicrobial dosage needs to be adjusted based on patients' renal and hepatic function.
			Antimicrobials should be chosen based on in vitro susceptibility as well as patient drug allergies,
			intolerances, and potential drug interactions or contraindications to a specific antimicrobial. Clinical and
			laboratory monitoring for efficacy and safety should occur based on prior IDSA guidelines. The possibility
			of prolonged QTc interval and tendinopathy should be discussed and monitored when using fluoroquinolones.
			The possibility of <em>Clostridium difficile</em> colitis should also be discussed when using any
			antimicrobial.</p>
		<p><sup>b</sup> Flucloxacillin may be used in Europe. Oxacillin can also be substituted.</p>
		<p><sup>c</sup> There was not a consensus on the use of ceftriaxone for methicillin-susceptible staphylococci
			(see text).</p>
		<p><sup>d</sup> Target troughs for vancomycin should be chosen with the guidance of a local infectious disease
			physician based on the pathogen, its in vitro susceptibility, and the use of rifampin or local vancomycin
			therapy. Recent guidelines for the treatment of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)
			infections have been published. (These guidelines suggest that dosing of vancomycin be considered to achieve
			a vancomycin trough at steady state of 15 to 20. Although this may be appropriate for MRSA PJI treated
			without rifampin or without the use of local vancomycin spacer, it is unknown if these higher trough
			concentrations are necessary when rifampin or vancomcyin impregnated spacers are utilized. Trough
			concentrations of at least 10 may be appropriate in this situation. It is also unknown if treatment of
			oxacillin-resistant, coagulase-negative staphylococci require vancomycin dosing to achieve these higher
			vancomycin levels.)</p>
		<p><sup>e</sup> Other antipseudomonal carbapenems can be utilized as well.</p>
	</div>
	<hr/>
	<h3 class="unnumbered" id="references-3">References</h3>
	<ol>
		<li>
			<p>Berbari EF, Osmon DR, Steckelberg JM. Infective and reactive arthritis. In: Cohen J, Powderly WG,
				Berkley SF,
				Calandra T, Clumeck N, Finch RG, et al, editors. Infectious diseases. Vol 1. 2nd ed. Edinburgh:
				Mosby;
				c2004. p. 563-9</p>
		</li>
		<li>
			<p>Elie F. Berbari, James M. Steckelberg, Douglas R. Osmon,106 - Osteomyelitis, Editor(s): John E.
				Bennett,
				Raphael Dolin, Martin J. Blaser,Mandell, Douglas, and Bennett’s Principles and Practice of
				Infectious
				Diseases (Eighth Edition), W.B. Saunders, 2015, Pages 1318-1327.e2, ISBN 9781455748013, <a
					href="https://doi.org/10.1016/B978-1-4557-4801-3.00106-5">https://doi.org/10.1016/B978-1-4557-4801-3.00106-5</a>.
			</p>
		</li>
		<li>
			<p>(https://www.sciencedirect.com/science/article/pii/B9781455748013001065)</p>
		</li>
		<li>
			<p>Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty. A study of the treatment
				of one
				hundred and six infections. J Bone Joint Surg Am. 1996 Apr;78(4):512-23. doi:
				10.2106/00004623-199604000-00005. PMID: 8609130.</p>
		</li>
		<li>
			<p>Zimmerli, W., Trampuz, A., Ochsner, P.E., 2004. Prosthetic-Joint Infections. New England Journal of
				Medicine
				351, 1645&ndash;1654. doi:10.1056/nejmra040181</p>
		</li>
		<li>
			<p>Zimmerli, W., 1998. Role of Rifampin for Treatment of Orthopedic Implant&ndash;Related Staphylococcal
				Infections A
				Randomized Controlled Trial. JAMA 279, 1537.. doi:10.1001/jama.279.19.1537</p>
		</li>
	</ol>
	</div>
	<footer></footer>
</body>

</html>